Copyright
©The Author(s) 2021.
World J Clin Cases. Jun 26, 2021; 9(18): 4690-4699
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4690
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4690
Table 3 Reductions in hepatitis B virus DNA level in trial participants in the two groups (log10 IU/mL)
| HBeAg-positive CHB | HBeAg-negative CHB | |||||
| Group | n | 72 wk (mean ± SD) | 96 wk (mean ± SD) | n | 72 wk (mean ± SD) | 96 wk (mean ± SD) |
| A | 114 | 5.72 ± 1.01 | 5.77 ± 0.99 | 47 | 4.49 ± 1.19 | 4.46 ± 1.19 |
| B | 118 | 5.75 ± 0.84 | 5.73 ± 1.01 | 51 | 4.67 ± 1.22 | 4.70 ± 1.18 |
| P value | 0.8514 | 0.6843 | 0.5528 | 0.3644 | ||
- Citation: Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World J Clin Cases 2021; 9(18): 4690-4699
- URL: https://www.wjgnet.com/2307-8960/full/v9/i18/4690.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i18.4690